Michael S.  Brown net worth and biography

Michael Brown Biography and Net Worth

Michael S. Brown, M.D., has been a Director of the Company since June 1991. Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, is a Regental Professor of Molecular Genetics and Internal Medicine, and the Director of the Jonsson Center for Molecular Genetics at the University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Dr. Brown and Dr. Joseph Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985. Dr. Brown is a member of the National Academy of Sciences, the Institute of Medicine and Foreign Member of the Royal Society (London).  Dr. Brown served as a member of the Board of Directors of Pfizer Inc.until April 2012.

What is Michael S. Brown's net worth?

The estimated net worth of Michael S. Brown is at least $1.13 million as of December 27th, 2023. Dr. Brown owns 1,247 shares of Regeneron Pharmaceuticals stock worth more than $1,132,987 as of April 23rd. This net worth approximation does not reflect any other assets that Dr. Brown may own. Learn More about Michael S. Brown's net worth.

How do I contact Michael S. Brown?

The corporate mailing address for Dr. Brown and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Michael S. Brown's contact information.

Has Michael S. Brown been buying or selling shares of Regeneron Pharmaceuticals?

Michael S. Brown has not been actively trading shares of Regeneron Pharmaceuticals during the last ninety days. Most recently, Michael S. Brown sold 2,049 shares of the business's stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $898.00, for a transaction totalling $1,840,002.00. Following the completion of the sale, the director now directly owns 1,247 shares of the company's stock, valued at $1,119,806. Learn More on Michael S. Brown's trading history.

Who are Regeneron Pharmaceuticals' active insiders?

Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Regeneron Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 29 times. They sold a total of 56,015 shares worth more than $48,626,379.06. The most recent insider tranaction occured on March, 14th when EVP Andrew J Murphy sold 5,783 shares worth more than $5,531,266.01. Insiders at Regeneron Pharmaceuticals own 8.8% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.

Information on this page was last updated on 3/14/2024.

Michael S. Brown Insider Trading History at Regeneron Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/27/2023Sell2,049$898.00$1,840,002.001,247View SEC Filing Icon  
4/21/2023Sell3,070$798.42$2,451,149.401,247View SEC Filing Icon  
1/27/2023Sell1$747.00$747.001,247View SEC Filing Icon  
3/30/2022Sell408$699.00$285,192.00View SEC Filing Icon  
9/13/2021Sell9,704$648.16$6,289,744.646,328View SEC Filing Icon  
8/9/2021Sell1,687$612.38$1,033,085.06View SEC Filing Icon  
6/25/2021Sell2,084$549.00$1,144,116.002,975View SEC Filing Icon  
1/25/2021Sell2,480$554.32$1,374,713.603,371View SEC Filing Icon  
7/1/2020Sell3,613$607.62$2,195,331.064,256View SEC Filing Icon  
11/12/2019Sell4,500$349.00$1,570,500.004,823View SEC Filing Icon  
9/27/2018Sell2,000$392.26$784,520.002,000View SEC Filing Icon  
8/22/2018Sell1,500$380.49$570,735.001,500View SEC Filing Icon  
10/5/2017Sell1,500$475.00$712,500.00View SEC Filing Icon  
6/20/2017Sell3,000$500.00$1,500,000.003,000View SEC Filing Icon  
5/12/2017Sell3,000$450.00$1,350,000.003,000View SEC Filing Icon  
3/29/2017Sell1,000$400.00$400,000.001,000View SEC Filing Icon  
12/10/2015Sell3,000$546.45$1,639,350.00View SEC Filing Icon  
9/21/2015Sell3,000$551.55$1,654,650.00View SEC Filing Icon  
5/15/2015Sell5,000$495.00$2,475,000.00View SEC Filing Icon  
10/24/2014Sell5,000$399.00$1,995,000.00View SEC Filing Icon  
8/15/2014Sell3,000$349.20$1,047,600.00View SEC Filing Icon  
5/17/2013Sell15,000$275.19$4,127,850.00View SEC Filing Icon  
11/14/2012Sell7,000$147.03$1,029,210.00View SEC Filing Icon  
See Full Table

Michael S. Brown Buying and Selling Activity at Regeneron Pharmaceuticals

This chart shows Michael S Brown's buying and selling at Regeneron Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Read More

Today's Range

Now: $908.57
Low: $903.83
High: $912.74

50 Day Range

MA: $952.07
Low: $893.99
High: $993.35

2 Week Range

Now: $908.57
Low: $684.80
High: $998.33

Volume

126,781 shs

Average Volume

488,505 shs

Market Capitalization

$99.72 billion

P/E Ratio

26.15

Dividend Yield

N/A

Beta

0.11